So our inaugural CSO paper- our manifesto- is just out with invitation to all stakeholders to join our movement. Common Sense Oncology is all about outcomes that matter to our patients, and how to ensure that our goals are aligned towards improving these outcomes. thelancet.com/journals/lanon… 1/

⚠️ SPOILER ALERT for K-drama fans ⚠️ In #QueenOfTears, Hae-in's fictional "cloud cell tumor/"cloud cytoma" most closely resembles gliomatosis cerebri. 🔗 radiopaedia.org/cases/gliomato…

Learn how to harness the power of social media to empower our patients with the right tools and information. See you tomorrow 1 PM at SMX Convention Center Function Room 3 as I kick off the IM Digital and Human track of #PCP2024 pre-con!

Read the May 2024 issue of The Oncologist, now online Oxford Journals: academic.oup.com/oncolo/issue/2… #OpenAccess

This review provides a comprehensive overview of the current evidence on cancer-related cognitive impairment (CRCI). Recognizing CRCI's impact can help clinicians develop personalized interventions and preventive approaches. IRCCS San Camillo Research Hospital #SuppOnc doi.org/10.1093/oncolo…

⚠️ Did you know that #HERBAL/DIETARY #SUPPLEMENTS are 𝑵𝑶𝑻 allowed to claim that they can treat/prevent disease? ❌ This is 𝒂𝒈𝒂𝒊𝒏𝒔𝒕 FDA Philippines Ad Standards Council policies: 🔗 fda.gov.ph/wp-content/upl… 🔗 asc.com.ph/wp-content/upl… 👇🏼 How often do you encounter these ad violations?

We’re expanding our collaboration w/ American Cancer Society to create an online resource for people w/ cancer. Starting 6/3, Cancer.Net will redirect to Cancer.org for comprehensive content from ACS & ASCO. Read more: brnw.ch/21wKkBF #ASCO24

And now... updated results of 41 patients CURATIVELY treated with 6m of Dostarlimab (PD-1) WITHOUT ☢️or🔪 ✅100% cCR rate ✅0 Local or distance relapses ✅Sustained cCR for > 12 m seen in 20 patients with mFU of 29 m THIS. IS. AWESOME #ASCO24

ESMO is pleased to share the ESMO Presidential Election election results: G Curigliano MD PhD (Italy) will be the ESMO President 2027-2028 and will join the ESMO Executive Board on 1 January 2025 as President-Elect. 👉ow.ly/Si8g50SgGlQ

Efficacy of first-line treatment options in advanced EGFR-mutated NSCLC From Stephanie P. L. Saw's presentation at #ASCO24 OncoAlert

Most patients don't realize their doctors and nurses think about them in the spaces between visits. While walking to the parking lot, driving home, brushing teeth… even before falling asleep. Our work is a part of us, and we really care about you. That's all.

The Common Sense Oncology movement is one to which we should all belong Dr Deme Karikios #bct2024 - Promote hope, not hype (and interpret all studies critically) - PFS doesn’t always translate to OS or QoL (the outcomes that matter to our patients) - We need to talk financial toxicity

Different eGFR formulas resulted in comparable % of #cisplatin-unfit pts with muscle-invasive #BladderCancer. Measured CrCl is recommended when calculated eGFR=40-59 mL/min as a significant number of patients could be reclassified as cisplatin-fit. European Association of Urology (EAU) doi.org/10.1093/oncolo…

OncoAlert Proudly announces5⃣ NEW CATALYST Fellowships, exclusively for Oncologists working in LMIC's wanting to do research with our faculty🚨 APPLICATION DEADLINE SEPTEMBER 1st, 2024 Contact us for details: oncoalert360.com/the-catalyst-f… #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa